RS50057B - OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE - Google Patents

OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE

Info

Publication number
RS50057B
RS50057B YUP-2005/0411A YU41105A RS50057B RS 50057 B RS50057 B RS 50057B YU 41105 A YU41105 A YU 41105A RS 50057 B RS50057 B RS 50057B
Authority
RS
Serbia
Prior art keywords
controlled release
oxycodone
oxycodon
compositions
water
Prior art date
Application number
YUP-2005/0411A
Other languages
Serbian (sr)
Inventor
Benjamin OSHLACK
John Joseph Minogue
Robert Francis Kaiko
Mark Chasin
Original Assignee
Euro-Celtique S.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A., filed Critical Euro-Celtique S.A.,
Publication of YU20050411A publication Critical patent/YU20050411A/en
Publication of RS50057B publication Critical patent/RS50057B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Postupak proizvodnje formulacije sa kontrolisanim oslobađanj em koja .sadrži. so oksikodona inkorporisanu u matrici za kontrolisano oslobađanje, naznačen time, što se (a) formiraj u granule koj e sadrže bar jednu vodorastvornu hidroksialkil celulozu i so oksikodona, vlažnom granulacijom sa vodom; (b) mešanju granula koje sadrže hidroksialkil celulozu sa bar jednim C12-C36alifatskim alkoholom; gde pomenuta formulacija sadržr 10 do 160 mg oksikodon hidrohlorida; pomenuta formulacij a sa kontrolisanim oslobađanjem se koristi da prihvatljivo kontroliše bol kod suštinski svih humanih pacijenata, pri ravnotežnom stanju posle ponovljenog davanja 10 do 160 mg oksikodon hidrohlorida u 12-časovnim intervalima. Prijava sadrži još 22 zahteva.A process for the production of a controlled release formulation containing. an oxycodone salt incorporated in a controlled release matrix (a) formed into granules containing at least one water-soluble hydroxyalkyl cellulose and oxycodone salt by wet granulation with water; (b) mixing the granules containing hydroxyalkyl cellulose with at least one C12-C36aliphatic alcohol; wherein said formulation contains 10 to 160 mg of oxycodone hydrochloride; said controlled release formulation is used to tolerate pain control in substantially all human patients at steady state after repeated administration of 10 to 160 mg of oxycodone hydrochloride at 12-hour intervals. The application contains 22 more requests.

YUP-2005/0411A 1992-11-25 1993-05-21 OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE RS50057B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1014692A 1992-11-25 1992-11-25

Publications (2)

Publication Number Publication Date
YU20050411A YU20050411A (en) 2006-08-17
RS50057B true RS50057B (en) 2008-11-28

Family

ID=37616752

Family Applications (2)

Application Number Title Priority Date Filing Date
YUP-2005/0411A RS50057B (en) 1992-11-25 1993-05-21 OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE
YUP-2005/0413A RS50058B (en) 1992-11-25 1993-05-21 OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE

Family Applications After (1)

Application Number Title Priority Date Filing Date
YUP-2005/0413A RS50058B (en) 1992-11-25 1993-05-21 OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE

Country Status (2)

Country Link
ME (6) MEP47808A (en)
RS (2) RS50057B (en)

Also Published As

Publication number Publication date
MEP47708A (en) 2011-02-10
MEP47508A (en) 2011-02-10
MEP47908A (en) 2011-02-10
MEP47808A (en) 2011-02-10
MEP48008A (en) 2011-02-10
RS50058B (en) 2008-11-28
MEP47608A (en) 2011-02-10
YU20050413A (en) 2006-08-17
YU20050411A (en) 2006-08-17

Similar Documents

Publication Publication Date Title
DE3877764D1 (en) A FREE-FLOWING GRANULATE, CONTAINING IBUPROFEN AND A PRODUCTION PROCESS.
ES2068800T1 (en) PHARMACEUTICAL PREPARATION IN THE FORM OF AN EFFERVESCENT OR DISINTEGRATION TABLET OR AN INSTANTLY SOLUBLE GRANULATE, AND PROCEDURE FOR ITS PRODUCTION.
YU49069B (en) Procedure for the manufacture of formulation tablet
RS50054B (en) OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE
ES8707109A1 (en) A therapeutic effervescent composition and a method of preparing the same.
DK0560092T3 (en) Tablets, granules and pellets with high content of active substances for highly concentrated solid administration forms
CA2062428A1 (en) Low dose dry pharmaceutical preparations
DK582287A (en) MEDIUM FOR PREPARING SOLID DOSAGE FORMS WITH UNIFORM AND DELAYED RELEASE
EP0267702A3 (en) Spray dried acetaminophen
PT90466A (en) PREPARATION PROCESS OF PHARMACEUTICAL COMPOSITIONS COMPOSING AN EXTRAGRANULAR EXCIPIENT, INSOLUBLE HYGROSCOPE IN WATER AND AN ACTIVE INGREDIENT, IN PARTICULAR CIMETIDINE
CA1261271A (en) Solid medicament formulation containing nitrendipine and a process for its preparation
UA5328A1 (en) Method for obtaining tablets
SE8204581L (en) PHARMACEUTICAL EXCIPIENTS
KR880000090A (en) Method for preparing sustained release ibuprofen formulation
EA200001201A2 (en) Matrix tablet for prolonged release of trimetazidine
DK0456720T3 (en) Granules with high ibuprofen content
SE8901003D0 (en) QUICKLY PREPARATION
KR840004347A (en) Stabilization of Unstable Drugs or Food Additives
RS50057B (en) OXYCODON COMPOSITIONS WITH CONTROLLED RELEASE
WO1997010810A3 (en) Pharmaceutical granules
ATE212550T1 (en) MEDICINAL PREPARATIONS CONTAINING TIAGABINE WITH CONTROLLED ADMINISTRATION OF ACTIVE INGREDIENTS
JPS5535047A (en) Dry syrup
SE8001121L (en) ANTI-HYPERTENSIVE PHARMACEUTICAL PREPARATIONS
KR20030056474A (en) Manufacturing Method & Formulation of Controlled-release Carbidopa/Levodopa Tablets
SI9200080B (en) Pharmaceutical preparations containing compressed medicaments granules